200 related articles for article (PubMed ID: 25192639)
1. Behavioral and neuropathological consequences of transient global ischemia in APP/PS1 Alzheimer model mice.
Kemppainen S; Hämäläinen E; Miettinen PO; Koistinaho J; Tanila H
Behav Brain Res; 2014 Dec; 275():15-26. PubMed ID: 25192639
[TBL] [Abstract][Full Text] [Related]
2. Effects of accelerated senescence on learning and memory, locomotion and anxiety-like behavior in APP/PS1 mouse model of Alzheimer's disease.
Lok K; Zhao H; Zhang C; He N; Shen H; Wang Z; Zhao W; Yin M
J Neurol Sci; 2013 Dec; 335(1-2):145-54. PubMed ID: 24095271
[TBL] [Abstract][Full Text] [Related]
3. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
Zhang W; Hao J; Liu R; Zhang Z; Lei G; Su C; Miao J; Li Z
Behav Brain Res; 2011 Sep; 222(2):342-50. PubMed ID: 21513747
[TBL] [Abstract][Full Text] [Related]
4. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
[TBL] [Abstract][Full Text] [Related]
5. Behavioral abnormalities in APPSwe/PS1dE9 mouse model of AD-like pathology: comparative analysis across multiple behavioral domains.
Janus C; Flores AY; Xu G; Borchelt DR
Neurobiol Aging; 2015 Sep; 36(9):2519-32. PubMed ID: 26089165
[TBL] [Abstract][Full Text] [Related]
6. Spatial Memory Impairment is Associated with Intraneural Amyloid-β Immunoreactivity and Dysfunctional Arc Expression in the Hippocampal-CA3 Region of a Transgenic Mouse Model of Alzheimer's Disease.
Morin JP; Cerón-Solano G; Velázquez-Campos G; Pacheco-López G; Bermúdez-Rattoni F; Díaz-Cintra S
J Alzheimers Dis; 2016; 51(1):69-79. PubMed ID: 26836189
[TBL] [Abstract][Full Text] [Related]
7. Gene Dosage Dependent Aggravation of the Neurological Phenotype in the 5XFAD Mouse Model of Alzheimer's Disease.
Richard BC; Kurdakova A; Baches S; Bayer TA; Weggen S; Wirths O
J Alzheimers Dis; 2015; 45(4):1223-36. PubMed ID: 25697701
[TBL] [Abstract][Full Text] [Related]
8. Anomalies in social behaviors and exploratory activities in an APPswe/PS1 mouse model of Alzheimer's disease.
Filali M; Lalonde R; Rivest S
Physiol Behav; 2011 Oct; 104(5):880-5. PubMed ID: 21640739
[TBL] [Abstract][Full Text] [Related]
9. Visuo-spatial learning and memory deficits on the Barnes maze in the 16-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
O'Leary TP; Brown RE
Behav Brain Res; 2009 Jul; 201(1):120-7. PubMed ID: 19428625
[TBL] [Abstract][Full Text] [Related]
10. Comparative studies using the Morris water maze to assess spatial memory deficits in two transgenic mouse models of Alzheimer's disease.
Edwards SR; Hamlin AS; Marks N; Coulson EJ; Smith MT
Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):798-806. PubMed ID: 25115283
[TBL] [Abstract][Full Text] [Related]
11. The impact of Bdnf gene deficiency to the memory impairment and brain pathology of APPswe/PS1dE9 mouse model of Alzheimer's disease.
Rantamäki T; Kemppainen S; Autio H; Stavén S; Koivisto H; Kojima M; Antila H; Miettinen PO; Kärkkäinen E; Karpova N; Vesa L; Lindemann L; Hoener MC; Tanila H; Castrén E
PLoS One; 2013; 8(7):e68722. PubMed ID: 23844236
[TBL] [Abstract][Full Text] [Related]
12. Physical exercise protects against Alzheimer's disease in 3xTg-AD mice.
García-Mesa Y; López-Ramos JC; Giménez-Llort L; Revilla S; Guerra R; Gruart A; Laferla FM; Cristòfol R; Delgado-García JM; Sanfeliu C
J Alzheimers Dis; 2011; 24(3):421-54. PubMed ID: 21297257
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition.
Stumm C; Hiebel C; Hanstein R; Purrio M; Nagel H; Conrad A; Lutz B; Behl C; Clement AB
Neurobiol Aging; 2013 Nov; 34(11):2574-84. PubMed ID: 23838176
[TBL] [Abstract][Full Text] [Related]
14. Histological and Behavioral Phenotypes of a Novel Mutated APP Knock-In Mouse.
Plucińska K; Crouch B; Yeap JM; Stoppelkamp S; Riedel G; Platt B
J Alzheimers Dis; 2018; 65(1):165-180. PubMed ID: 30040726
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal behavioral changes in the APP/PS1 transgenic Alzheimer's disease model.
Ferguson SA; Sarkar S; Schmued LC
Behav Brain Res; 2013 Apr; 242():125-34. PubMed ID: 23295401
[TBL] [Abstract][Full Text] [Related]
16. Intensive 'Brain Training' Intervention Fails to Reduce Amyloid Pathologies or Cognitive Deficits in Transgenic Mouse Models of Alzheimer's Disease.
Anderson M; Xu F; Ou-Yang MH; Davis J; Van Nostrand WE; Robinson JK
J Alzheimers Dis; 2017; 55(3):1109-1121. PubMed ID: 27767989
[TBL] [Abstract][Full Text] [Related]
17. The role of neuroinflammation and amyloid in cognitive impairment in an APP/PS1 transgenic mouse model of Alzheimer's disease.
Zhu S; Wang J; Zhang Y; He J; Kong J; Wang JF; Li XM
CNS Neurosci Ther; 2017 Apr; 23(4):310-320. PubMed ID: 28191738
[TBL] [Abstract][Full Text] [Related]
18. Characterization of cognition alteration across the course of the disease in APP751SL mice with parallel estimation of cerebral Abeta deposition.
Blanchard J; Decorte L; Noguès X; Micheau J
Behav Brain Res; 2009 Jul; 201(1):147-57. PubMed ID: 19428628
[TBL] [Abstract][Full Text] [Related]
19. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease.
Guo C; Wang T; Zheng W; Shan ZY; Teng WP; Wang ZY
Neurobiol Aging; 2013 Feb; 34(2):562-75. PubMed ID: 22717236
[TBL] [Abstract][Full Text] [Related]
20. Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits.
Jardanhazi-Kurutz D; Kummer MP; Terwel D; Vogel K; Dyrks T; Thiele A; Heneka MT
Neurochem Int; 2010 Nov; 57(4):375-82. PubMed ID: 20144675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
